110
Views
6
CrossRef citations to date
0
Altmetric
Review

The new concepts on overcoming drug resistance in lung cancer

, , &
Pages 735-744 | Published online: 06 Jun 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Dorra Abdelmalek, Fahmi Smaoui, Fakher Frikha, Riadh ben Marzoug, Dhouha Msalbi, Amal Souissi & Mohamed Sami Aifa. (2023) Computational identification of new TKI as potential noncovalent reversible EGFRL858R/T790M inhibitors: VHTS, molecular docking, DFT study and molecular dynamic simulation. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-18.
Read now
Yunyao Ye, Jingyao Gu, Pei Liu, He Wang, Lihua Jiang, Tianyao Lei, Shanxun Yu, Gaohua Han & Zhaoxia Wang. (2020) Long Non-Coding RNA SPRY4-IT1 Reverses Cisplatin Resistance by Downregulating MPZL-1 via Suppressing EMT in NSCLC. OncoTargets and Therapy 13, pages 2783-2793.
Read now
Pei Wang, Dong Chen, Hongbing Ma & Yong Li. (2017) LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. OncoTargets and Therapy 10, pages 5137-5149.
Read now
Seung-Hun Kim, Chun-Yen Liu, Po-Wei Fan, Chang-Heng Hsieh, Hsuan-Yuan Lin, Ming-Chung Lee & Kang Fang. (2016) The aqueous extract of Brucea javanica suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor. Drug Design, Development and Therapy 10, pages 3599-3609.
Read now

Articles from other publishers (2)

Long-fei Mao, Zhen-Zhen Wang, Qiong Wu, Xiaojie Chen, Jian-Xue Yang, Xin Wang & Yue-Ming Li. (2022) Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives. Frontiers in Pharmacology 13.
Crossref
Fotis Nikolos, Christoforos Thomas, Igor Bado & Jan-Åke Gustafsson. (2018) ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response. Molecular Cancer Research 16:2, pages 233-242.
Crossref